Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT02238808

A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers (PRESTO)

PRe-operative ESTradiOl Window of Opportunity Study in Post-Menopausal Women With Newly Diagnosed ER Positive Breast Cancer

Sponsor: AHS Cancer Control Alberta

Conditions Estrogen Receptor Positive Breast Cancer

Interventions Estradiol

Updated 9 times since 2017 Last updated: Jun 24, 2025 Started: Aug 31, 2015 Primary completion: Jul 30, 2018 Completion: Jun 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Estrogen Receptor Positive Breast Cancer, this trial is ongoing. The trial is conducted by AHS Cancer Control Alberta and has accumulated 9 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Jul 2025 — Present [monthly]

Active Not Recruiting PHASE2
Sep 2024 — Jul 2025 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Mar 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2021 — Mar 2023 [monthly]

Active Not Recruiting PHASE2

▶ Show 4 earlier versions

Mar 2019 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE2
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AHS Cancer Control Alberta

Data source: AHS Cancer Control Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada